Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 13/20 | 0.49 |
| ▸ | CA1 | P00915 | 13/20 | 0.49 |
| ▸ | CA2 | P00918 | 13/20 | 0.49 |
| ▸ | CA9 | Q16790 | 13/20 | 0.49 |
| ▸ | CA7 | P43166 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24257959 | 0.93 | ALDH1A1 (0.49) | CA12CA1CA2CA9CA7 | |
| SCHEMBL24257964 | 0.89 | CA12 (0.52) | CA12CA1CA2CA9CA7 | |
| SCHEMBL24257976 | 0.88 | CA2 (0.54) | CA12CA1CA2CA9CA7 | |
| SCHEMBL24257965 | 0.83 | CA2 (0.52) | CA12CA1CA2CA9CA7 | |
| SCHEMBL22080330 | 0.78 | CA2 (0.58) | CA12CA1CA2CA9CA7 | |
| SCHEMBL22080315 | 0.76 | SOS1 (0.51) | CA12CA1CA2CA9CA7 | |
| SCHEMBL22029358 | 0.74 | ITGB1 (0.49) | CA12CA1CA2CA9CA7 | |
| SCHEMBL31682090 | 0.74 | ITGB1 (0.49) | CA12CA1CA2CA9CA7 | |
| SCHEMBL31682046 | 0.74 | ITGB1 (0.49) | CA12CA1CA2CA9CA7 | |
| SCHEMBL23343702 | 0.73 | CA2 (0.58) | CA12CA1CA2CA9CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048968-A1 | INSULIN CONJUGATES | SANOFI (FR) | 2022-02-17 | — | — | US | disclosed |
| US-20200181223-A1 | INSULIN CONJUGATES | SANOFI (FR) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181223-A1 | INSULIN CONJUGATES | IAPP, INSR, IGF1R | CA12 453/4885CA1 1162/4885CA2 1521/4885 |
| US-20220048968-A1 | INSULIN CONJUGATES | IAPP, INSR, IGF1R | CA12 453/4885CA1 1162/4885CA2 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.